Patents by Inventor Naoya Maekawa
Naoya Maekawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11781146Abstract: The present invention provides mammalian cell expression vectors that impart to mammalian host cells an ability to produce high levels of foreign gene-derived proteins. A ubiquitously acting chromatin opening element (UCOE) is introduced into an expression vector that has a plasmid DNA integrated into a transcriptional hot spot on the chromosome of a dihydrofolate reductase gene-deficient host cell so that it allows for selection of strains that grow in hypoxanthine-thymidine (hereinafter denoted as HT)-free medium, whereby transformants will produce a protein of interest in increased amounts.Type: GrantFiled: May 13, 2019Date of Patent: October 10, 2023Assignees: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Yasuhiko Suzuki, Miki Nakagawa, Yayoi Kameda, Satoru Konnai, Tomohiro Okagawa, Naoya Maekawa, Shinya Goto, Yamato Sajiki, Kazuhiko Ohashi, Shiro Murata, Yuzuru Kitahara, Keiichi Yamamoto
-
Patent number: 11697686Abstract: The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDP (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.Type: GrantFiled: October 28, 2020Date of Patent: July 11, 2023Assignees: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Satoshi Takagi, Yumiko Kagawa, Yasuhiko Suzuki, Chie Nakajima
-
Publication number: 20220227871Abstract: The present invention provides an anti-PD-L1 antibody capable of repeated administration even to animals other than rat. An anti-PD-L1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLYSENQKDY (SEQ ID NO: 37), CDR2 having the amino acid sequence of WAT and CDR3 having the amino acid sequence of GQYLVYPFT (SEQ ID NO: 38) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GYTFTSNF (SEQ ID NO: 39), CDR2 having the amino acid sequence of IYPEYGNT (SEQ ID NO: 40) and CDR3 having the amino acid sequence of ASEEAVISLVY (SEQ ID NO: 41) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-PD-L1 antibody as an active ingredient. A method for preparing the above anti-PD-L1 antibody is also provided.Type: ApplicationFiled: January 19, 2022Publication date: July 21, 2022Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
-
Patent number: 11312773Abstract: The present invention provides an anti-PD-L1 antibody capable of repeated administration even to animals other than rat. An anti-PD-L1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLYSENQKDY (SEQ ID NO: 37), CDR2 having the amino acid sequence of WAT and CDR3 having the amino acid sequence of GQYLVYPFT (SEQ ID NO: 38) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GYTFTSNF (SEQ ID NO: 39), CDR2 having the amino acid sequence of IYPEYGNT (SEQ ID NO: 40) and CDR3 having the amino acid sequence of ASEEAVISLVY (SEQ ID NO: 41) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-PD-L1 antibody as an active ingredient. A method for preparing the above anti-PD-L1 antibody is also provided.Type: GrantFiled: August 10, 2017Date of Patent: April 26, 2022Assignees: Fuso Pharmaceutical Industries, Ltd., National University Corporation Hokkaido UniversityInventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
-
Patent number: 11198730Abstract: The present invention provides an anti-LAG-3 antibody capable of repeated administration even to animals other than rat. An anti-LAG-3 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLDSDGNTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of SVS and CDR3 having the amino acid sequence of MQATHVPFT (SEQ ID NO: 17) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFDFDTYP (SEQ ID NO: 18), CDR2 having the amino acid sequence of ITIKTHNYAT (SEQ ID NO: 19) and CDR3 having the amino acid sequence of NREDFDY (SEQ ID NO: 20) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-LAG-3 antibody as an active ingredient. A method for preparing the above anti-LAG-3 antibody is also provided.Type: GrantFiled: August 10, 2017Date of Patent: December 14, 2021Assignees: Fuso Pharmaceutical Industries, Ltd., National University Corporation Hokkaido UniversityInventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
-
Publication number: 20210277124Abstract: The present invention provides an anti-PD-L1 antibody capable of repeated administration even to animals other than rat. An anti-PD-L1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLYSENQKDY (SEQ ID NO: 37), CDR2 having the amino acid sequence of WAT and CDR3 having the amino acid sequence of GQYLVYPFT (SEQ ID NO: 38) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GYTFTSNF (SEQ ID NO: 39), CDR2 having the amino acid sequence of IYPEYGNT (SEQ ID NO: 40) and CDR3 having the amino acid sequence of ASEEAVISLVY (SEQ ID NO: 41) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-PD-L1 antibody as an active ingredient. A method for preparing the above anti-PD-L1 antibody is also provided.Type: ApplicationFiled: August 10, 2017Publication date: September 9, 2021Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
-
Publication number: 20210254079Abstract: The present invention provides mammalian cell expression vectors that impart to mammalian host cells an ability to produce high levels of foreign gene-derived proteins. A ubiquitously acting chromatin opening element (UCOE) is introduced into an expression vector that has a plasmid DNA integrated into a transcriptional hot spot on the chromosome of a dihydrofolate reductase gene-deficient host cell so that it allows for selection of strains that grow in hypoxanthine-thymidine (hereinafter denoted as HT)-free medium, whereby transformants will produce a protein of interest in increased amounts.Type: ApplicationFiled: May 12, 2019Publication date: August 19, 2021Applicants: National University Corporation Hokkaido University, Fuso Pharmaceutical Industries, Ltd.Inventors: Yasuhiko SUZUKI, Miki NAKAGAWA, Yayoi KAMEDA, Satoru KONNAI, Tomohiro OKAGAWA, Naoya MAEKAWA, Shinya GOTO, Yamato SAJIKI, Kazuhiko OHASHI, Shiro MURATA, Yuzuru KITAHARA, Keiichi YAMAMOTO
-
Publication number: 20210079095Abstract: The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDF (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.Type: ApplicationFiled: October 28, 2020Publication date: March 18, 2021Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Satoshi Takagi, Yumiko Kagawa, Yasuhiko Suzuki, Chie Nakajima
-
Patent number: 10865246Abstract: The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDF (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.Type: GrantFiled: March 23, 2018Date of Patent: December 15, 2020Assignees: Fuso Pharmaceutical Industries, Ltd., National University Corporation Hokkaido UniversityInventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Satoshi Takagi, Yumiko Kagawa, Yasuhiko Suzuki, Chie Nakajima
-
Publication number: 20200131270Abstract: The present invention provides a novel therapeutic strategy using an inhibitor targeting PD-1/PD-L1. A pharmaceutical composition which comprises a COX-2 inhibitor and is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1. A potentiator for the immunostimulatory effect of an inhibitor targeting PD-1/PD-L1, which comprises a COX-2 inhibitor.Type: ApplicationFiled: July 19, 2018Publication date: April 30, 2020Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Satoru KONNAI, Kazuhiko OHASHI, Shiro MURATA, Tomohiro OKAGAWA, Naoya MAEKAWA, Asami NISHIMORI, Shinya GOTO, Yasuhiko SUZUKI, Chie NAKAJIMA, Yamato SAJIKI
-
Publication number: 20200031932Abstract: The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDF (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.Type: ApplicationFiled: March 23, 2018Publication date: January 30, 2020Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Satoshi Takagi, Yumiko Kagawa, Yasuhiko Suzuki, Chie Nakajima
-
Publication number: 20190185568Abstract: The present invention provides an anti-PD-1 antibody capable of repeated administration even to animals other than rat. An anti-PD-1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLEYSDGYTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of GVS and CDR3 having the amino acid sequence of FQATHDPDT (SEQ ID NO: 17) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFSLTSYY (SEQ ID NO: 18), CDR2 having the amino acid sequence of IRSGGST (SEQ ID NO: 19) and CDR3 having the amino acid sequence of ARTSSGYEGGFDY (SEQ ID NO: 20) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above-described anti-PD-1 antibody as an active ingredient. A method for preparing the anti-PD-1 antibody is also provided.Type: ApplicationFiled: August 10, 2017Publication date: June 20, 2019Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
-
Publication number: 20190169294Abstract: The present invention provides an anti-LAG-3 antibody capable of repeated administration even to animals other than rat. An anti-LAG-3 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLDSDGNTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of SVS and CDR3 having the amino acid sequence of MQATHVPFT (SEQ ID NO: 17) and the light chain constant region of an antibody of an animal other than rat; and (h) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFDFDTYP (SEQ ID NO: 18), CDR2 having the amino acid sequence of ITIKTHNYAT (SEQ ID NO: 19) and CDR3 having the amino acid sequence of NREDFDY (SEQ ID NO: 20) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-LAG-3 antibody as an active ingredient. A method for preparing the above anti-LAG-3 antibody is also provided.Type: ApplicationFiled: August 10, 2017Publication date: June 6, 2019Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
-
Patent number: 9319582Abstract: Herein describes, by example, a digital image device comprising a CCD image sensor, a setting dial, a controller, and an image processor. The CCD image sensor captures a subject image and outputs image information. The setting dial accepts an input operation and outputs an operation signal including one that corresponds to the direction of the dial. The controller sets an object region that will be the object of a specific image processing process, so that at least one of a region direction and a region range for setting the object region can be changed according to an operation signal corresponding to the operation direction of the interface component. The image processor performs diorama filtering on the object region on the basis of the region direction and the region range.Type: GrantFiled: June 27, 2012Date of Patent: April 19, 2016Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.Inventor: Naoya Maekawa
-
Publication number: 20130002899Abstract: Herein describes, by example, a digital image device comprising a CCD image sensor, a setting dial, a controller, and an image processor. The CCD image sensor captures a subject image and outputs image information. The setting dial accepts an input operation and outputs an operation signal including one that corresponds to the direction of the dial. The controller sets an object region that will be the object of a specific image processing process, so that at least one of a region direction and a region range for setting the object region can be changed according to an operation signal corresponding to the operation direction of the interface component. The image processor performs diorama filtering on the object region on the basis of the region direction and the region range.Type: ApplicationFiled: June 27, 2012Publication date: January 3, 2013Applicant: Panasonic CorporationInventor: Naoya MAEKAWA
-
Patent number: 7794619Abstract: A refrigeration lubricant composition contains an ester compound obtained from a polyol and a fatty acid, and a five- or six-membered ring cyclic ether compound having a side chain with an ester bonding. The content of the cyclic ether compound is adjusted to 0.01 to 5 parts by mass based on 100 parts by mass of the ester compound.Type: GrantFiled: March 27, 2008Date of Patent: September 14, 2010Assignee: NOF CorporationInventors: Takeshi Kajiki, Naoya Maekawa
-
Publication number: 20080237534Abstract: A refrigeration lubricant composition contains an ester compound obtained from a polyol and a fatty acid, and a five- or six-membered ring cyclic ether compound having a side chain with an ester bonding. The content of the cyclic ether compound is adjusted to 0.01 to 5 parts by mass based on 100 parts by mass of the ester compound.Type: ApplicationFiled: March 27, 2008Publication date: October 2, 2008Applicant: NOF CORPORATIONInventors: Takeshi Kajiki, Naoya Maekawa